Research Papers:

Survivin overexpression is potentially associated with pituitary adenoma invasiveness

Xiangyi Kong, Shun Gong, Lijuan Su, Xinqi Cheng, Honglei Li, Tingting You and Yanguo Kong _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:105637-105647. https://doi.org/10.18632/oncotarget.22354

Metrics: PDF 1223 views  |   HTML 1738 views  |   ?  


Xiangyi Kong1,2,*, Shun Gong3,4,*, Lijuan Su5,*, Xinqi Cheng6, Honglei Li6, Tingting You6 and Yanguo Kong1

1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China

2Department of Breast Surgical Oncology, China National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Panjiayuan, Beijing 100021, P.R. China

3Department of Neurosurgery, Shanghai Institute of Neurosurgery, PLA Institute of Neurosurgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China

4Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02215, United States of America

5College of Computer Science and Technology, Zhejiang University, Hangzhou, Zhejiang 310027, P.R. China

6Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, P.R. China

*These authors have contributed equally to this work

Correspondence to:

Yanguo Kong, email: [email protected]

Keywords: survivin; pituitary adenoma; invasiveness

Received: February 21, 2017    Accepted: June 30, 2017    Published: November 10, 2017


Background and objective: Survivin is an inhibitor of apoptosis. Its role in guiding the treatment of neoplasms, making diagnosis and predicting prognosis has been reported. However, there is little information on the implications and uses of survivin in predicting pituitary adenoma (PA) invasiveness. Existing information is unclear and controversial. We thus conducted this meta-analysis to explore whether the surviving expression levels in invasive PAs (IPA) and regular PAs are different or not. We considered both non-secreting and secreting tumors together.

Methods: A global search strategy was systematically applied among five databases including Cochrane Library, Embase, PubMed, Web of Science, and Chinese National Knowledge Infrastructure (CNKI) up to June 18th, 2017. With a specially designed form including PAs’ invasive features, etc., data was collected. The included studies should present the data representing the surviving levels in IPA groups and regular PA groups, respectively. Differences were expressed as standard mean differences (SMDs) or odds ratios (ORs) with 95% confidence interval (CI). To estimate the heterogeneities, I2 test, Cochran’s Q-test and Galbr figure were all conducted. A sensitivity-analysis and potential-publication bias were also performed.

Results: In the present meta-analysis, 9 studies containing 489 patients were included. Seven studies with dichotomous-data showed that survivin over-expression in PA tissue was closely associated with a high invasive tendency (OR 6.226, 95% CI 3.970, 9.765; P<0.001), but 2 continuous-data studies revealed that there was no significant association (SMD -5.043, 95% CI-10.965, 0.878; p=0.095). A sensitivity-analysis suggested a statistically stable result. We did not find publication bias.

Conclusion: We suggest that survivin overexpression is potentially associated with PA invasiveness. More research based on medical big data is needed to confirm this finding.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22354